PetMed Express's revenue for the
three
months ended in Mar. 2026 was $42.8 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $179.0 Mil.
PetMed Express's Revenue per Share for the
three
months ended in Mar. 2026 was $2.04.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $8.56.
Warning Sign:
PetMed Express Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of PetMed Express was -22.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -11.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -9.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -2.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, PetMed Express's highest 3-Year average Revenue per Share Growth Rate was 58.00% per year. The lowest was -11.10% per year. And the median was 4.90% per year.
PetMed Express (NAS:PETS) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
PetMed Express Revenue Related Terms
PetMed Express Revenue Historical Data
* Premium members only.
The historical data trend for PetMed Express's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, PetMed Express's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PetMed Express Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PetMed Express's Revenue distribution charts can be found below:
* The bar in red indicates where PetMed Express's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $179.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PetMed Express (PETS) has a Revenue of $179.0 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on PetMed Express and its competitors.
Is PetMed Express' Revenue too high?
PetMed Express' current Revenue is $179.0 Mil. Overall, PetMed Express has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PetMed Express' Revenue compare to SHFH and BHIC?
PetMed Express' Revenue of $179.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on PetMed Express and its competitors. PetMed Express's current Revenue is $179.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PetMed Express stock overvalued right now?
Based on GuruFocus' analysis, PetMed Express (PETS) is currently considered Possible Value Trap. The stock's GF Value™ is $2.87, compared to a current price of $1.95 — trading 32% below its estimated fair value. The current Revenue is $179.0 Mil. PetMed Express' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For PetMed Express (PETS), the current Revenue is $179.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PetMed Express (PETS) Overvalued in 2026?
Based on GuruFocus' analysis, PetMed Express stock appears to be undervalued.
The current stock price of $1.95 is trading 32% below its estimated GF Value™ of $2.87.
GuruFocus considers PetMed Express to be Possible Value Trap.
Key valuation signals for PETS:
Revenue: $179.0 Mil
GF Value™: $2.87 vs. price of $1.95 (32% below fair value)
No single metric tells the full story. See the PETS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PetMed Express Inc is a nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies, and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile application, offering convenience, price, speed of delivery, and customer service. It provides access to branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and AutoShip capabilities. Its digital platform offers pet healthcare solutions for chronic conditions, including allergies, arthritis, anxiety, kidney-related conditions, and hyperthyroidism.
60GF Score
Get the complete analysis for PETS
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PETS has been successfully added to your 
